Skip to main content

Table 4 Effect of host and HIV-1 viral factors on day 7 and 28 changes in HIV-1 plasma viral load

From: Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections

Variables Categories HIV-1 VL0–7 (N = 30) HIV-1 VL0–28 (N = 22)
Mean rank U/χ2 (df) p value Mean rank U/χ2 (df) p value
HBV status HIV alone 10.00 (n = 11) 44.0 0.300 12.20 (n = 10) 33.0 0.218
Co-infection 13.00 (n = 11) 8.80 (n = 10)
Sex Male 12.86 (n = 7) 43.0 0.503 15.35 (n = 9) 19.0 0.020
Female 10.87 (n = 15) 8.29 (n = 11)
WHO clinical stage Stage 1 4.25 (n = 2) 2.794 (2) 0.247 9.00 (n = 1) 0.068 (2) 0.966
Stage 2 12.09 (n = 17) 10.56 (n = 16)
Stage 3 13.00 (n = 3) 10.67 (n = 3)
Antiretroviral drugs d4T + 3TC + EFV 11.00 (n = 2) 0.737 (3) 0.864 10.50 (n = 2) 3.182 (3) 0.364
d4T + 3TC + NVP 12.83 (n = 6) 9.75 (n = 4)
CBV + EFV 12.25 (n = 8) 13.13 (n = 8)
CBV + NVP 10.06 (n = 8) 7.50 (n = 6)
Mutations Present 5.75 (n = 2) 8.5 0.292 9.5 (n = 4) 26.0 0.878
Absent 10.75 (n = 17) 10.75 (n = 16)
HIV-1 subtype 02AG 10.41 (n = 17) 24 0.410 9.5 (n = 4) 37 0.898
Non 02AG 13.50 (n = 4) 10.75 (n = 16)
  1. Significant p values are in italics
  2. U, Mann–Whitney U test; χ2 (df), Kruskal–Wallis H test; Co-infection, HIV and HBV co-infection; VL 0–7 HIV-1 plasma viral load changes after 7 days of therapy; VL 0–28 HIV-1 plasma viral load changes after 28 days of therapy